After Catalent rumors, Danaher strikes $5.7B deal to acquire antibody specialist Abcam

It’s a sale. Two months after Abcam launched a strategic review of the company, the British antibody research expert has revealed that it’s being bought by Danaher.

Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday. The deal, which is worth about $5.7 billion, is expected to close in mid-2024.